-
Mashup Score: 1Boost in Genomic Testing, Multidisciplinary Input Needed for Personalized Lung Cancer Care - 2 year(s) ago
Nagashree Seetharamu, MD, MBBS, discusses the importance of early and frequent genomic testing in patients with lung cancer, as well as remaining challenges faced in clinical practice and efforts being made to overcome them.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Clinical Trials Needed to Determine the Utility of Targeted Therapies in Oncogene-Driven Locally Advanced NSCLC - 2 year(s) ago
Julie Renee Brahmer, MD, MSc, discusses remaining questions regarding immunotherapy and targeted therapy in locally advanced NSCLC, data from the phase 3 PACIFIC and ADAURA trials, and her hopes for future clinical trials in the paradigm.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@JulieBrahmer discusses remaining questions regarding immunotherapy in locally advanced NSCLC, data from the phase 3 PACIFIC and ADAURA trials, and her hopes for future clinical trials in the paradigm. @HopkinsMedicine @gotoPER #gotoPER #gotoNYLung #lcsm https://t.co/H3RPFDgjud
-
-
Mashup Score: 0Boost in Genomic Testing, Multidisciplinary Input Needed for Personalized Lung Cancer Care - 2 year(s) ago
Nagashree Seetharamu, MD, MBBS, discusses the importance of early and frequent genomic testing in patients with lung cancer, as well as remaining challenges faced in clinical practice and efforts being made to overcome them.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@NagashreeSeeth1, discusses the importance of early and frequent genomic testing in patients with lung cancer, as well as remaining challenges faced in clinical practice & efforts being made. @NorthwellHealth @gotoPER #gotoPER #gotoNYLung #lcsm https://t.co/4SO6CJQCHo
-
-
Mashup Score: 0Clinical Trials Needed to Determine the Utility of Targeted Therapies in Oncogene-Driven Locally Advanced NSCLC - 2 year(s) ago
Julie Renee Brahmer, MD, MSc, discusses remaining questions regarding immunotherapy and targeted therapy in locally advanced NSCLC, data from the phase 3 PACIFIC and ADAURA trials, and her hopes for future clinical trials in the paradigm.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Although adjuvant treatment w/ durvalumab after chemoradiation has transformed the management of NSCLC, the lack of benefit observed in EGFR mutations underscores the need to develop clinical trials @JulieBrahmer @HopkinsMedicine @gotoPER #gotoNYLung #lcsm https://t.co/BJRSg1s7fD https://t.co/IbIj22q5QW
-
-
Mashup Score: 2Boost in Genomic Testing, Multidisciplinary Input Needed for Personalized Lung Cancer Care - 3 year(s) ago
Nagashree Seetharamu, MD, MBBS, discusses the importance of early and frequent genomic testing in patients with lung cancer, as well as remaining challenges faced in clinical practice and efforts being made to overcome them.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Boost in Genomic Testing, Multidisciplinary Input Needed for Personalized Lung Cancer Care @NagashreeSeeth1 @NorthwellHealth @gotoPER #gotoPER #gotoNYLung #lcsm https://t.co/xtwL3Jg2Ek
-
-
Mashup Score: 1Research With Cellular Therapy Ramps Up in Mesothelioma - 3 year(s) ago
Marjorie G. Zauderer, MD, previews some of the new approaches in mesothelioma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Research With Cellular Therapy Ramps Up in Mesothelioma @MGZauderer @sloan_kettering @gotoPER #gotoPER #gotoNYLung #lcsm https://t.co/7Z5OQIBjY3
-
-
Mashup Score: 1Clinical Trials Needed to Determine the Utility of Targeted Therapies in Oncogene-Driven Locally Advanced NSCLC - 3 year(s) ago
Julie Renee Brahmer, MD, MSc, discusses remaining questions regarding immunotherapy and targeted therapy in locally advanced NSCLC, data from the phase 3 PACIFIC and ADAURA trials, and her hopes for future clinical trials in the paradigm.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Clinical Trials Needed to Determine the Utility of Targeted Therapies in Oncogene-Driven Locally Advanced NSCLC @JulieBrahmer @HopkinsMedicine @gotoPER #gotoPER #gotoNYLung #lcsm https://t.co/JbVVrrofsk
-
-
Mashup Score: 1Cancer Conference - 16th Annual New York Lung Cancers Symposium® - 3 year(s) ago
Lung Cancer Conference | New York Lung Cancers Symposium®, is offering a comprehensive overview of lung cancer diagnoses & multidisciplinary treatment
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The 16th Annual New York Lung Cancers Symposium®, now both live and virtual, will feature a discussion on new approaches for mesothelioma. Register now: https://t.co/lQ503XzwTy #gotoPER #gotoNYLung #LungCancer https://t.co/MnwfEn0O1H
-
-
Mashup Score: 0Cancer Conference - 16th Annual New York Lung Cancers Symposium® - 3 year(s) ago
Lung Cancer Conference | New York Lung Cancers Symposium®, is offering a comprehensive overview of lung cancer diagnoses & multidisciplinary treatment
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Don’t miss this hybrid interactive conference to learn how medical and surgical oncology departments can collaborate to improve outcomes in stage II non-small cell lung cancer. Register now: https://t.co/lQ503XzwTy #gotoPER #gotoNYLung #LungCancer https://t.co/Et9oCnux12
-
-
Mashup Score: 1Cancer Conference - 16th Annual New York Lung Cancers Symposium® - 3 year(s) ago
Lung Cancer Conference | New York Lung Cancers Symposium®, is offering a comprehensive overview of lung cancer diagnoses & multidisciplinary treatment
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Receive a comprehensive education on multidisciplinary interventions key to maximize outcomes with the use of adjuvant and neoadjuvant approaches to lung cancer care. Join us virtually or live on November 6: https://t.co/lQ503XzwTy #gotoPER #gotoNYLung #LungCancer @EinsteinMed https://t.co/MI6htGlTlg
-
Patients with lung cancer should undergo genomic testing at the time of disease progression so that insight can be gained on the genomic transformation of the tumor @NagashreeSeeth1 @NorthwellHealth @gotoPER #gotoPER #gotoNYLung #lcsm https://t.co/ulI5aML9La https://t.co/zg0faP2HB8